Rajesh Kumar
Stock Analyst at HSBC
(2.87)
# 1,486
Out of 5,049 analysts
26
Total ratings
52.94%
Success rate
9%
Average return
Main Sectors:
Stocks Rated by Rajesh Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IQV IQVIA Holdings | Upgrades: Buy | $195 → $235 | $210.86 | +11.45% | 2 | Oct 9, 2025 | |
| NVO Novo Nordisk | Upgrades: Buy | $70 | $46.51 | +50.51% | 2 | Oct 2, 2025 | |
| ABBV AbbVie | Downgrades: Hold | n/a | $219.04 | - | 4 | Oct 1, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Hold | $675 → $700 | $937.44 | -25.33% | 3 | Aug 27, 2025 | |
| KDP Keurig Dr Pepper | Upgrades: Buy | $36 → $42 | $26.36 | +59.33% | 1 | Apr 25, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Buy | $660 → $670 | $565.98 | +18.38% | 3 | Apr 30, 2024 | |
| DHR Danaher | Upgrades: Buy | $250 → $280 | $210.67 | +32.91% | 2 | Apr 17, 2024 | |
| UNH UnitedHealth Group | Upgrades: Hold | $460 | $321.56 | +43.05% | 2 | Apr 4, 2024 | |
| TEVA Teva Pharmaceutical Industries | Initiates: Buy | $13 | $24.46 | -46.85% | 1 | Dec 18, 2023 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Hold | $55 → $53 | $46.63 | +13.66% | 2 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Reduce | $97 | $24.33 | +298.68% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $124 | $103.35 | +19.98% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $24.85 | +101.21% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $123 | $85.78 | +43.39% | 1 | Jul 14, 2023 |
IQVIA Holdings
Oct 9, 2025
Upgrades: Buy
Price Target: $195 → $235
Current: $210.86
Upside: +11.45%
Novo Nordisk
Oct 2, 2025
Upgrades: Buy
Price Target: $70
Current: $46.51
Upside: +50.51%
AbbVie
Oct 1, 2025
Downgrades: Hold
Price Target: n/a
Current: $219.04
Upside: -
Eli Lilly and Company
Aug 27, 2025
Upgrades: Hold
Price Target: $675 → $700
Current: $937.44
Upside: -25.33%
Keurig Dr Pepper
Apr 25, 2025
Upgrades: Buy
Price Target: $36 → $42
Current: $26.36
Upside: +59.33%
Thermo Fisher Scientific
Apr 30, 2024
Maintains: Buy
Price Target: $660 → $670
Current: $565.98
Upside: +18.38%
Danaher
Apr 17, 2024
Upgrades: Buy
Price Target: $250 → $280
Current: $210.67
Upside: +32.91%
UnitedHealth Group
Apr 4, 2024
Upgrades: Hold
Price Target: $460
Current: $321.56
Upside: +43.05%
Teva Pharmaceutical Industries
Dec 18, 2023
Initiates: Buy
Price Target: $13
Current: $24.46
Upside: -46.85%
Bristol-Myers Squibb Company
Oct 27, 2023
Upgrades: Hold
Price Target: $55 → $53
Current: $46.63
Upside: +13.66%
Jul 14, 2023
Initiates: Reduce
Price Target: $97
Current: $24.33
Upside: +298.68%
Jul 14, 2023
Initiates: Buy
Price Target: $124
Current: $103.35
Upside: +19.98%
Jul 14, 2023
Initiates: Buy
Price Target: $50
Current: $24.85
Upside: +101.21%
Jul 14, 2023
Initiates: Hold
Price Target: $123
Current: $85.78
Upside: +43.39%